Company Overview and News

11
FDA Places Clinical Hold on Ziopharma’s Sleeping Beauty CAR-T Therapy

11h biospace
The U.S. Food and Drug Administration (FDA) placed a clinical hold on Boston-based ZIOPHARM Oncology’s Phase I trial of its Sleeping Beauty CAR-T therapy.
MKGAF MKGAY XON

20
Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy

14h globenewswire
BOSTON, June 18, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the U.S. Food and Drug Administration (FDA) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional information in support of the investigational new drug (IND) application for the trial.
ZIOP MKGAF XON MKGAY

481
Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

2018-06-13 seekingalpha
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP

27
Recent Industry Movement Focuses on Depression Treatments

2018-06-08 biospace
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs), such as Prozac and Zoloft, or serotonin-norepinephrine reuptake inhibitors (SNRIs), like Pristiq or Efexor. But there are still individuals who do not respond well to these drugs and the industry continues to work on developing better and alternative treatments for depression. There has been quite a bit of activity in this area recently.
SAGE MKGAF MKGAY VTGN

187
Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline

2018-06-03 seekingalpha
Overlooked specialty contract development and manufacturing stock in the exciting field of advanced cell therapy with a potential for an exponential upside.
LZAGY MKGAF PFZ C O6Z MS.PRE CRSP MS.PRF MS.PRG MS.PRA PFIZER BAC CDMO MS.PRI MKGAY MS.PRK 4502 MS ORGS 500680 PFE WXXWY LZAGF

43
Consider This a Warning on Cancer-Drug Combos - Bloomberg

2018-06-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GNMSF MKGAF GMXAY MKGAY AZN INCY

52
German Stocks For Dividend Growth Investing

2018-05-31 seekingalpha
US markets have done extremely well in last several years and a cautious investor may wish to diversify their portfolio. Diversification comes in many shapes and forms. I am personally interested in diversifying across industries, geographies, political landscapes and currencies. As an avid dividend growth investor, I try to find global dividend growth companies that can additionally de-risk my portfolio while providing an avenue to benefit from worldwide economic growth.
MKGAF DB PG UL MKGAY ADDYY NXTM TSLA DMLRY

11
Vertex Pharmaceuticals (VRTX) Down 1.2% Since Earnings Report: Can It Rebound?

2018-05-28 zacks
It has been about a month since the last earnings report for Vertex Pharmaceuticals Incorporated (VRTX - Free Report) . Shares have lost about 1.2% in that time frame.
DUKH VRTX MKGAF MKGAY ITW HTH DUK

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-28 globenewswire
GENT, België, 28 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 24 mei 2018 een kennisgeving van deelneming heeft ontvangen van Sanofi S.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-28 globenewswire
GHENT, Belgium, 28 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Sanofi S.A. on 24 May 2018.
MKGAF MKGAY ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-28 globenewswire
GENT, België, 28 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij kennisgevingen van deelneming heeft ontvangen van Farallon Capital Management, LLC; Marshall Wace LLP; Van Herk Investments B.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-28 globenewswire
GHENT, Belgium, 28 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received notifications of shareholdings from Farallon Capital Management, LLC; Marshall Wace LLP; Van Herk Investments B.
MKGAF MKGAY ABYLY ABLX ABLYF

120
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo

2018-05-22 zacks
Chicago, IL – May 22, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Procter & Gamble (PG - Free Report) , AbbVie (ABBV - Free Report) , McDonald’s (MCD - Free Report) and PepsiCo (PEP - Free Report) .
CCS MKGAF BUD RL PEP MKGAY HEAR AHBIF ABBV URBN CSIQ ABBV MCD AKAM

120
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo

2018-05-22 zacks
Chicago, IL – May 22, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Procter & Gamble (PG - Free Report) , AbbVie (ABBV - Free Report) , McDonald’s (MCD - Free Report) and PepsiCo (PEP - Free Report) .
CCS MKGAF BUD RL PEP MKGAY HEAR AHBIF ABBV URBN CSIQ ABBV MCD AKAM

166
Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo

2018-05-21 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including Procter & Gamble (PG), AbbVie (ABBV), McDonald’s (MCD) and PepsiCo (PEP). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
HD MKGAF GD UPS ABB SRE.PRA PEP MKGAY SRE AMAT ABLZF ABBV CSX ABBV MCD

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 004741844